About us
Discovering innovative cancer therapies
From initial concept to the delivery of candidate drugs through to the clinic, Sentinel Oncology specializes in discovering cutting-edge treatments for oncology and diseases with a high unmet need.
Our beginning
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat patients for whom there is currently an unmet medical need.
Our core strength is the development of highly selective and targeted oncology candidate drugs. Our pipeline strategy is focused on the design and optimisation of new drugs which can be used to treat primary brain tumours or systemic tumours which frequently metastasise to the brain.
Our portfolio includes three late-stage preclinical programmes positioned to enter phase 1 clinical trials during 2023. Sentinel Oncology is a fully integrated drug discovery company developing high quality drug candidates for partnering with the pharmaceutical and biotechnology sectors.
Our business model is collaborative, and we partner with organisations who can maximise the value of our programmes. Our track record is proven by the recent licensing of both the Chk1 and S6K1 programs.
Our science
